Archives
-
ATP Solution for mRNA Research Workflows
2026-08-28
ATP Solution (100 mM) supports reproducible transcription, kinase, ligation, and phosphorylation workflows that underpin mRNA therapeutic research. This article connects reagent control with the localized p21 mRNA–LNP strategy for bladder cancer while separating evidence from practical optimization recommendations.
-
Ibrexafungerp (MK 3118): Mechanism and Evidence
2026-08-27
Ibrexafungerp, also called MK 3118 or SCY-078, is an oral triterpenoid antifungal that inhibits fungal 1,3-β-D-glucan synthase. Clinical approval covers vulvovaginal candidiasis and reduction of recurrent VVC, while peer-reviewed susceptibility data support activity against many echinocandin-resistant Candida isolates.
-
Mubritinib: Complex I Workflows in Cancer Research
2026-08-27
Mubritinib (TAK 165) supports mechanism-led studies that connect mitochondrial complex I inhibition, oxidative stress, and apoptosis across AML, PEL, and NSCLC models. This guide translates published cisplatin-sensitization findings into practical dosing, assay-selection, troubleshooting, and validation workflows.
-
From Hippo Biology to High-Sensitivity Tissue Maps
2026-08-26
Spatially restricted Hippo signaling creates a demanding imaging problem: researchers must distinguish rare, developmentally immature hepatobiliary states without sacrificing tissue context. This thought-leadership article connects those biological questions to Cy5 tyramide signal amplification, offering a practical framework for validating low-abundance markers in liver development, regeneration, and translational pathology.
-
LY-411575: An Assay-First Guide to γ-Secretase
2026-08-26
LY-411575 is a high-potency gamma-secretase inhibitor for dissecting amyloid beta and Notch biology. This assay-first guide explains how to interpret its subnanomolar activity, select informative readouts, and avoid confusing pathway suppression with functional benefit.
-
Angiotensin 1/2 (1-6): Assay Design Guide
2026-08-25
Explore Angiotensin 1/2 (1-6) and its Asp-Arg-Val-Tyr-Ile-His sequence through a rigorous assay-design framework. This guide connects renin-angiotensin system biology with receptor-binding evidence while clarifying controls, limitations, and practical workflows.
-
TRIB3, Ferroptosis, and Sunitinib Response in ccRCC
2026-08-25
The reference study identifies TRIB3 as a contributor to clear cell renal cell carcinoma resistance to sunitinib and connects its depletion with ferroptosis through the SLC7A11/GPX4 axis. By combining bioinformatic analysis with cellular validation, the work suggests that TRIB3 suppression may improve drug response, while also defining important experimental controls for studying ferroptosis in ccRCC.
-
TCAIM Control of OGDH and Mitochondrial Metabolism
2026-08-24
The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that specifically binds native OGDH and promotes its reduction through HSPA9 and LONP1. This mechanism links mitochondrial proteostasis to control of OGDH complex activity and carbohydrate catabolism, offering a new framework for studying post-translational metabolic regulation.
-
Phenacetin as a PK Reference in Translational Assays
2026-08-24
Phenacetin offers a chemically defined reference point for pharmacokinetic studies, solubility assessment, and translational assay design. This article distinguishes its value as a workflow control from the target-specific biology of emerging PDK4 inhibitors.
-
UTP Solution (100 mM) for RNA Workflows
2026-08-23
UTP Solution (100 mM) provides a contamination-controlled uridine nucleotide input for in vitro transcription, RNA amplification, siRNA synthesis, and selected nucleotide-metabolism assays. This guide connects practical reagent handling with the TRIM66 olfactory-receptor study, showing how robust RNA production can support mechanistic and low-input experiments without overstating what the nucleotide itself proves.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-22
The 2025 study shows that naturally occurring angiotensin fragments can enhance SARS-CoV-2 spike-protein binding to host receptors, with effects determined by peptide length, terminal sequence, and tyrosine modification. Its antibody-based binding design provides a useful framework for connecting renin-angiotensin system research with viral receptor biology while emphasizing that biochemical binding is not equivalent to demonstrated infection or clinical risk.
-
Deferoxamine Mesylate in Ferroptosis Workflows
2026-08-22
Deferoxamine mesylate gives researchers a practical way to manipulate labile iron while separating iron-dependent lipid damage from plasma-membrane execution events. This guide shows how to use it as a ferroptosis rescue control, hypoxia-mimetic reagent, and oxidative stress protection tool without confusing chelation with TMEM16F inhibition.
-
Angiotensin I/II (1-5): RAS Workflow Guide
2026-08-21
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving blood pressure, renal, and aldosterone-related readouts. It is intended for cardiovascular and renal workflows, not general peptide-signaling studies, and its water insolubility requires deliberate solvent, vehicle, and storage controls.
-
RNAi Screen Reveals SARS-CoV-2 Release Factors
2026-08-20
Kerr et al. developed an arrayed, druggable-genome RNA interference screen that measures SARS-CoV-2 production at multiple stages, reducing the bias toward early replication factors. The study identifies Rab11a-linked vesicular transport as a conserved proviral pathway and shows that CDK9 inhibitor-73 can block viral release, supporting further investigation of host-directed antiviral mechanisms.
-
Baicalein in Redox-Aware Cancer Assays
2026-08-20
Baicalein is a 12-LOX-inhibiting flavonoid for dissecting cancer, apoptosis, and inflammatory signaling. This guide builds beyond standard mechanism summaries by showing how to pair pathway engagement with orthogonal redox and cell-selectivity assays.